EAM
PCRX icon

Eagle Asset Management’s Pacira BioSciences PCRX Stock Holding History

Eagle Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-131,724
Closed -$3.75M – 589
2024
Q2 		$3.75M Sell
131,724
-559
-0.4% -$15.9K 0.02% 420
2024
Q1 		$3.86M Sell
132,283
-1,717
-1% -$52.7K 0.02% 419
2023
Q4 		$4.52M Sell
134,000
-2,393
-2% -$70K 0.02% 384
2023
Q3 		$4.18M Buy
136,393
+62,597
+85% +$2.26M 0.02% 377
2023
Q2 		$2.96M Buy
+73,796
New +$3.05M 0.02% 411
2015
Q2 		– Sell
-331,560
Closed -$29.5M – 665
2015
Q1 		$29.5M Sell
331,560
-6,522
-2% -$662K 0.17% 177
2014
Q4 		$30M Buy
338,082
+20,099
+6% +$1.9M 0.17% 180
2014
Q3 		$30.8M Buy
317,983
+17,881
+6% +$1.74M 0.18% 171
2014
Q2 		$27.6M Buy
300,102
+93,342
+45% +$7.11M 0.15% 194
2014
Q1 		$14.5M Buy
+206,760
New +$14.1M 0.08% 295
2013
Q4 		– Sell
-170,764
Closed -$8.11M – 647
2013
Q3 		$8.11M Buy
+170,764
New +$6.22M 0.04% 402

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Eagle Asset Management's PCRX Position: Q3 2024 in Review

Eagle Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 131,724 shares — an estimated $3.75M sold.

Eagle Asset Management first reported a position in PCRX in Q3 2013 and held it in 11 quarters. The position peaked at $30.8M in Q3 2014. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Eagle Asset Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Eagle Asset Management sold 131,724 Pacira BioSciences shares in Q3 2024, an estimated $3.75M.
  • Eagle Asset Management first reported a position in Pacira BioSciences in Q3 2013 and held it in 11 quarters.
  • Eagle Asset Management's Pacira BioSciences position peaked at $30.8M in Q3 2014.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.